Personal information

Emails & domains

Verified email domains

Websites & social links

Fred Hutch Faculty Profile

Countries

United States

Activities

Collapse all

Employment (2)

University of Washington: Seattle, WA, US

2014-10 to present | Affiliate Assistant Professor (Department of Pharmacy)
Employment
Source: Self-asserted source
Joshua A Roth

Fred Hutchinson Cancer Research Center: Seattle, WA, US

2014-08 to present | Assistant Member (Hutchinson Institute for Cancer Outcomes Research)
Employment
Source: Self-asserted source
Joshua A Roth

Education and qualifications (2)

University of Washington: Seattle, WA, US

2008 to 2012 | Doctorate of Pharmaceutical Outcomes Research and Policy (Department of Pharmacy)
Education
Source: Self-asserted source
Joshua A Roth

University of Washington: Seattle, WA, US

2004 to 2008 | Masters of Health Services Administration (Department of Health Services)
Education
Source: Self-asserted source
Joshua A Roth

Funding (1)

UW Patient-Centered Outcomes Research Career Development Program

2014-08 to 2016-08 | Award
Agency for Healthcare Research and Quality (MD, MD, US)
GRANT_NUMBER:

1K12HS022982-01
Source: Self-asserted source
Joshua A Roth

Works (27)

Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review

BioDrugs
2025-02-26 | Journal article
DOI: 10.1007/s40259-025-00710-8
Contributors: Joshua A. Roth; Victoria W. Dayer; Mireia Jofre-Bonet; Alistair McGuire; Sean D. Sullivan
Source: check_circle
Crossref

A budget impact analysis of gene therapy for sickle cell disease: an updated analysis

Blood Advances
2024-09-10 | Journal article
DOI: 10.1182/bloodadvances.2024013093
Contributors: Patrick C. DeMartino; Meredith B. Haag; Aaron B. Caughey; Joshua A. Roth
Source: check_circle
Crossref

A descriptive analysis of real-world oncology biosimilar use in Japan

Future Oncology
2024-08-08 | Journal article
DOI: 10.1080/14796694.2024.2352405
Contributors: Joshua A Roth; Makan Rahshenas; Grégoire Nowacki; Nihar Masurkar; Ahmed Shelbaya; Kentaro Tajima; Stephanie Dorman; Chiho Ono
Source: check_circle
Crossref

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

JCO Oncology Practice
2024-04 | Journal article
DOI: 10.1200/OP.23.00413
Contributors: Wael Saber; Aasthaa Bansal; Lily Li; Bart L. Scott; Lindsey R. Sangaralingham; Viengneesee Thao; Joshua A. Roth; Winona Wright; Lotte M.G. Steuten; Joseph A. Pidala et al.
Source: check_circle
Crossref

Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101

Transplantation and Cellular Therapy
2023-07 | Journal article
DOI: 10.1016/j.jtct.2023.04.017
Contributors: Scott D. Ramsey; Aasthaa Bansal; Lily Li; Paul V. O'Donnell; Ephraim J. Fuchs; Claudio G. Brunstein; Mary Eapen; Viengneesee Thao; Joshua A. Roth; Lotte M.G. Steuten
Source: check_circle
Crossref

Translating an Economic Analysis into a Tool for Public Health Resource Allocation in Cancer Survivorship

MDM Policy & Practice
2023-01 | Journal article
DOI: 10.1177/23814683231153378
Contributors: Zachary Rivers; Joshua A. Roth; Winona Wright; Sun Hee Rim; Lisa C. Richardson; Cheryll C. Thomas; Julie S. Townsend; Scott D. Ramsey
Source: check_circle
Crossref

Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN)

JCO Oncology Practice
2021-11 | Journal article
DOI: 10.1200/OP.20.00770
Contributors: Joshua A. Roth; Meghna S. Trivedi; Stacy W. Gray; Donald L. Patrick; Debbie M. Delaney; Kate Watabayashi; Paul Litwin; Parth Shah; Katherine D. Crew; Monica Yee et al.
Source: check_circle
Crossref

A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer

Journal of Medical Economics
2021-01-01 | Journal article
DOI: 10.1080/13696998.2020.1857960
Contributors: Joshua A. Roth; Yong Yuan; Megan Othus; Mark Danese; Samuel Wagner; John R. Penrod; Scott D. Ramsey
Source: check_circle
Crossref

Value and affordability of CAR T-cell therapy in the United States

Bone Marrow Transplantation
2020-09-30 | Journal article
DOI: 10.1038/s41409-020-0956-8
Contributors: Salvatore Fiorenza; David S. Ritchie; Scott D. Ramsey; Cameron J. Turtle; Joshua A. Roth
Source: check_circle
Crossref

Intensity modulated radiation therapy following lumpectomy in early-stage breast cancer: Patterns of use and cost consequences among Medicare beneficiaries

PLOS ONE
2019-09-30 | Journal article
DOI: 10.1371/journal.pone.0222904
Contributors: Lia M. Halasz; Eugenio Paci; Shilpen A. Patel; Jean A. McDougall; Catherine Fedorenko; Qin Sun; Bernardo H. L. Goulart; Joshua A. Roth
Source: check_circle
Crossref

A qualitative study exploring patient motivations for screening for lung cancer

PLOS ONE
2018-07-05 | Journal article
DOI: 10.1371/journal.pone.0196758
Contributors: Joshua A. Roth; Nancy Lan Guo; Lisa Carter-Harris; Susan Brandzel; Diana S. M. Buist; Karen J. Wernli
Source: check_circle
Crossref

Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting

Pharmacoepidemiology and drug safety
2015 | Journal article
Source: Self-asserted source
Joshua A Roth

Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare

Journal of Oncology Practice
2015 | Journal article
Source: Self-asserted source
Joshua A Roth

The Relationship of Perceived Risk and Biases in Perceived Risk to Fracture Prevention Behavior in Older Women

Annals of Behavioral Medicine
2015 | Journal article
Source: Self-asserted source
Joshua A Roth

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States

2015 | Journal article
Source: Self-asserted source
Joshua A Roth

Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer

The oncologist
2014 | Journal article
Source: Self-asserted source
Joshua A Roth

Cost-effectiveness of a computerized provider order entry system in improving medication safety ambulatory care

Value in Health
2014 | Journal article
Source: Self-asserted source
Joshua A Roth

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer

Journal of comparative effectiveness research
2014 | Journal article
Source: Self-asserted source
Joshua A Roth

Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial: A Modeling Study

Annals of internal medicine
2014 | Journal article
Source: Self-asserted source
Joshua A Roth

Genetic risk factors for major bleeding in patients treated with warfarin in a community setting

Clinical Pharmacology & Therapeutics
2014 | Journal article
Source: Self-asserted source
Joshua A Roth

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Breast cancer research and treatment
2013 | Journal article
Source: Self-asserted source
Joshua A Roth

Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics

Medical Decision Making
2013 | Journal article
Source: Self-asserted source
Joshua A Roth

Cost-effectiveness of gemcitabine+ cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer

Journal of gastrointestinal cancer
2012 | Journal article
Source: Self-asserted source
Joshua A Roth

Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research

Genetics in Medicine
2012 | Journal article
Source: Self-asserted source
Joshua A Roth

Prognostic Role of ERCC1 in Advanced Non--Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Clinical lung cancer
2011 | Journal article
Source: Self-asserted source
Joshua A Roth

Stakeholder perspectives on a risk-benefit framework for genetic testing

Public Health Genomics
2011 | Journal article
Source: Self-asserted source
Joshua A Roth

A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice

Genetics in Medicine
2010 | Journal article
Source: Self-asserted source
Joshua A Roth
How many people are using ORCID?